EO2040 / Enterome - LARVOL DELTA

CLAUDE: EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (clinicaltrials.gov) - P2 | N=1 | Terminated | Sponsor: Enterome | Completed ➔ Terminated; the study recruitment is significantly behind expectations as only one single patient has started treatment

Circulating tumor DNA • Minimal residual disease • Trial termination • Colorectal Cancer • Oncology • Solid Tumor

CLAUDE: EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (clinicaltrials.gov) - P2 | N=1 | Completed | Sponsor: Enterome | Recruiting ➔ Completed | N=34 ➔ 1 | Trial completion date: Jan 2028 ➔ Dec 2023 | Trial primary completion date: Jun 2025 ➔ Dec 2023

Circulating tumor DNA • Combination therapy • Enrollment change • Minimal residual disease • Trial completion • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Enterome announces first patient dosed in Phase 2 trial with OncoMimics immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease (GlobeNewswire) - "Enterome...announces that the first patient has been dosed at The University of Texas MD Anderson Cancer Center (Houston, TX) in the Phase 2 'CLAUDE' trial evaluating EO2040, the Company's fourth OncoMimics™ immunotherapy candidate to enter clinical development. The CLAUDE trial will assess the immunogenicity and the preliminary efficacy of EO2040 in combination with nivolumab and as a monotherapy in patients with circulating tumor DNA (ctDNA) defined minimal residual disease (MRD) stage II-IV colorectal cancer (CRC) after completion of surgical resection and all other standard of care treatments."

Trial status • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics immunotherapy pipeline for solid and liquid tumors (GlobeNewswire) - "Enterome...announces the creation of its international Scientific Advisory Board (SAB) and Medical Advisory Group (MAG) comprising highly respected and influential scientific and clinical leaders in oncology and immunotherapy. The newly formed SAB and MAG will provide strategic, scientific, and clinical guidance to Enterome as it progresses its pipeline of innovative OncoMimics™ immunotherapies targeting solid and liquid tumors....'In addition, we look forward to their input to the development strategies around our other OncoMimics candidates, which are planned to enter clinical trials in 2023, including EO2040 in colorectal cancer with ctDNA-defined, minimal residual disease, and EO4010 for third-line colorectal cancer'."

New trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CLAUDE: EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Enterome | Trial completion date: Sep 2027 ➔ Jan 2028 | Trial primary completion date: Mar 2025 ➔ Jun 2025

Circulating tumor DNA • Combination therapy • Minimal residual disease • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CLAUDE: EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Enterome | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2022 ➔ Mar 2023

Circulating tumor DNA • Combination therapy • Enrollment open • Minimal residual disease • Trial initiation date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CLAUDE: EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (clinicaltrials.gov) - P2 | N=34 | Not yet recruiting | Sponsor: Enterome

Circulating tumor DNA • Combination therapy • Minimal residual disease • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor